Deep Brain Stimulation for Treatment Resistant Depression
| 대상 질환 | Major Depressive Disorder |
|---|---|
| 임상 단계 | 단계 해당 없음 |
| 스폰서 | Emory University |
| 상태 | 완료 |
| 참여자 수 | 37 명 |
| 중재(약물) | Deep Brain Stimulation |
| 시작일 | 2006년 9월 |
| 완료일 | 2014년 1월 2일 |
| 결과 공개일 | 2020년 7월 14일 |
요약
The purpose of this study is to test the safety, efficacy and mechanism of action of subgenual cingulate (Cg25) deep brain stimulation (DBS) for major depression in patients who have not responded to prior antidepressant treatments. Participation in the study will continue for ten years or until the device receives FDA approval for depression. Forty (40) patients will be enrolled in this study.
Change in Hamilton Depression Rating Scale-17 Score
| Deep Brain Stimulation | 23.6 ± 2.9 score on a scale |
|---|---|
| Deep Brain Stimulation | 11.66 ± 2.6 score on a scale |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- CBT+ for Depression — University of Wisconsin, Madison
- Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neu — Stanford University
- Severe Asthma, MepolizumaB and Affect: SAMBA Study — University Hospital Southampton NHS Foundation Trust
- Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for — Levomecor Inc.
- A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major De — Levomecor Inc.
- Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders — Massachusetts General Hospital